These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24142143)

  • 41. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K; Jung E; Fernández P; Zhao L; Harris B; Connor EM; Losonsky GA;
    Pediatr Infect Dis J; 2009 Apr; 28(4):267-72. PubMed ID: 19258920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
    Mitchell I
    South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
    [No Abstract]   [Full Text] [Related]  

  • 43. Defining the burden of respiratory syncytial virus infection.
    Mejias A; Ramilo O
    J Pediatr (Rio J); 2013; 89(6):517-9. PubMed ID: 24055097
    [No Abstract]   [Full Text] [Related]  

  • 44. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H
    Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
    Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
    Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Respiratory syncytial immunoprophylaxis with palivizumab].
    De Halleux V; Lombet J; Rigo J
    Rev Med Liege; 2007; 62(5-6):299-302. PubMed ID: 17725198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decision-making under conditions of uncertainty-what can we learn from palivizumab?
    Burls A; Sandercock J
    Acta Paediatr; 2011 Oct; 100(10):1302-5. PubMed ID: 21781158
    [No Abstract]   [Full Text] [Related]  

  • 48. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 50. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United States.
    Ambrose CS
    Pediatrics; 2014 Dec; 134(6):e1781. PubMed ID: 25452648
    [No Abstract]   [Full Text] [Related]  

  • 52. Response to respiratory synctial virus.
    Hampp C; Winterstein AG
    South Med J; 2008 Feb; 101(2):212-3; author reply 213-4. PubMed ID: 18364631
    [No Abstract]   [Full Text] [Related]  

  • 53. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study.
    Butt M; Symington A; Janes M; Steele S; Elliott L; Chant-Gambacort C; Mondal T; Paes B
    Cardiol Young; 2014 Apr; 24(2):337-43. PubMed ID: 23628233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].
    Figueras Aloy J; Carbonell Estrany X;
    An Pediatr (Barc); 2010 Aug; 73(2):98.e1-4. PubMed ID: 20621574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?
    Elnazir B; Oni O; Hassan T; Greally P; Paes B
    J Paediatr Child Health; 2012 Nov; 48(11):1033-8. PubMed ID: 23126393
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
    Aliamovskaia GA; Keshinian ES
    Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour.
    Resch B; Resch E; Müller W
    Paediatr Respir Rev; 2013 Jun; 14(2):130-6. PubMed ID: 23375547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.